Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐ <scp>PD</scp> ‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital
The prediction model developed in our study can screen and monitor patients with high risk of developing irAEs. It may improve prognosis for pan-cancer patients receiving anti-PD-(L)1 immunotherapy.
Authors
- Weijuan Tan (ORCID: https://orcid.org/0000-0002-0454-3980)
- Q. Q. Chen
- Panpan Jiao (ORCID: https://orcid.org/0009-0008-8832-2878)
- Juan Zhan (ORCID: https://orcid.org/0000-0002-2535-0811)
- Min Seok Song (ORCID: https://orcid.org/0000-0002-3738-9553)
- Chunling Ma (ORCID: https://orcid.org/0000-0003-1428-6495)
- S Q Lin
- Lijuan Xue
Institutions
- Xiamen University (CN)
- Zhongshan Hospital of Xiamen University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71603
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00